Novo Nordisk: Even Cash Cow Ozempic Hardly Justifies The Price

Dilok Klaisataporn My last article about Novo Nordisk A/S (NVO) was published in November 2023 and in the article, I argued that the price of Novo Nordisk could still be justified. In the meantime, the stock price increased almost 20% – after it has constantly increased at a high pace in the last few years. Novo Nordisk reported full-year results roughly two weeks ago, and we can ask once again if the stock price is justified. And not only can we ask for Novo Nordisk, but we can also take a brief look at the closest competitor – Eli Lilly…